[{"orgOrder":0,"company":"Biocytogen","sponsor":"LiberoThera","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BCG005","moa":"CCR8","graph1":"Oncology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ LiberoThera","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen \/ LiberoThera"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"YH008","moa":"CD40L receptor (CD40)","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Undisclosed"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Sotio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"SOT109","moa":"CDH17","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Sotio","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Sotio"},{"orgOrder":0,"company":"Biocytogen","sponsor":"TRACON Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin","moa":"||Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocytogen \/ TRACON Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Biocytogen \/ TRACON Pharmaceuticals"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"YH001","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocytogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biocytogen \/ Undisclosed"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Radiance Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"YH012","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Radiance Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Radiance Biopharma"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Eucure Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"YH001","moa":"||OX40L receptor (CD134)","graph1":"Oncology","graph2":"Phase I","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocytogen \/ Biocytogen","highestDevelopmentStatusID":"6","companyTruncated":"Biocytogen \/ Biocytogen"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Chia Tai Tianqing Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NTB003","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Chia Tai Tianqing Pharmaceutical Group","highestDevelopmentStatusID":"5","companyTruncated":"Biocytogen \/ Chia Tai Tianqing Pharmaceutical Group"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"RenNano","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ Undisclosed"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"RenNano","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ Undisclosed"},{"orgOrder":0,"company":"Biocytogen","sponsor":"BioCopy AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ BioCopy AG","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ BioCopy AG"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Myricx Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Myricx Bio","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Myricx Bio"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Pheon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Pheon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Pheon Therapeutics"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Xencor","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Xencor"},{"orgOrder":0,"company":"Biocytogen","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Janssen Biotech","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ Janssen Biotech"},{"orgOrder":0,"company":"Biocytogen","sponsor":"ABL Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ ABL Bio","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ ABL Bio"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Cmb International","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Series D Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0.14000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Cmb International","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Cmb International"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0.40999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.40999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Ideaya Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Ideaya Biosciences"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Adcendo","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Adcendo"},{"orgOrder":0,"company":"Biocytogen","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ ADC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ ADC Therapeutics"},{"orgOrder":0,"company":"Biocytogen","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ BeiGene","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ BeiGene"},{"orgOrder":0,"company":"Biocytogen","sponsor":"CtM Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ CtM Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ CtM Biotech"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Ona Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Ona Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Ona Therapeutics"},{"orgOrder":0,"company":"Biocytogen","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ BeOne Medicines","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ BeOne Medicines"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Neurocrine Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Guangzhou FineImmune Biotechnology Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Guangzhou FineImmune Biotechnology Co","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Guangzhou FineImmune Biotechnology Co"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Undisclosed"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Gilead Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ Gilead Sciences"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ Merck & Co"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ Merck & Co"},{"orgOrder":0,"company":"Biocytogen","sponsor":"CtM Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ CtM Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ CtM Biotech"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Tubulis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Tubulis","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Tubulis"}]

Find Clinical Drug Pipeline Developments & Deals by Biocytogen

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Tubulis has exercised an exclusive license for the global development and commercialization of a fully human antibody developed by Biocytogen.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          September 15, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Tubulis

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The agreement aims for further strengthening the strategic relationship between the two companies by accelerating innovative drug development for multiple fully human antibodies.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          July 09, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : BeOne Medicines

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : NTB003 is a second-generation fully human anti-IGF-1R monoclonal antibody, being investigated for thyroid eye disease.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 04, 2025

                          Lead Product(s) : NTB003

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Chia Tai Tianqing Pharmaceutical Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Under the licensing agreement, Sotio's SOT109 will leverage antibodies generated with Biocytogen RenMab platform as the backbone of ADC for colorectal cancer and other gastrointestinal cancers.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          January 09, 2025

                          Lead Product(s) : SOT109

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Sotio

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Under the terms of the agreement, Biocytogen will use cutting-edge platforms for antibody discovery to support Adcendo’s innovative ADC drug development for cancer.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 16, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Adcendo

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The Ideaya will focus on the novel ADC therapeutics for neoplasms through the license agreement for a potential first-in-class B7H3/PTK7 BsADC program with Biocytogen.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          July 31, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Ideaya Biosciences

                          Deal Size : $406.5 million

                          Deal Type : Licensing Agreement

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : BioCopy has gained access to TCR-mimic antibodies targeting intracellular antigens developed by Biocytogen’s proprietary RenTCR-mimic mice, to evaluate these antibodies for novel cancer therapies.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 06, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : BioCopy AG

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The collaboration aims to develop new bispecific antibody-drug conjugates using Biocytogen’s RenLite® mice platform that can produce fully human antibodies with diverse epitopes and high affinity.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 25, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : ABL Bio

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Through the collaboration, Gilead will be given access to Biocytogen’s extensive fully human antibody library generated against a wide range of therapeutic targets.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 19, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Sponsor : Gilead Sciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Radiance has an option to license YH012, a first-in-class anti-HER2/TROP2 bispecific antibody-drug conjugate from Biocytogen, for worldwide therapeutic development.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          January 08, 2024

                          Lead Product(s) : YH012

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Radiance Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank